Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of febuxostat (TMX-67) versus allopurinol for prevention of tumor lysis syndrome in cancer patients receiving chemotherapy
jRCT2080222348Phase 3
- Sponsor
- Teijin Pharma
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of febuxostat in tumor lysis syndrome (TLS), Non-hematologic malignancy and hematopoietic malignancies (2 arms), sponsored by Teijin Pharma.
02
Drugs
febuxostat
03
Conditions
tumor lysis syndrome (TLS)Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on jRCT2080222348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222348.